The LymeX Diagnostics Prize: Phase 4 Breakthroughs
The LymeX Innovation Accelerator, a $10 million public-private partnership between HHS and the Cohen Foundation, is entering its final clinical validation phase in 2026.
Next-Gen Tools: The prize has accelerated the development of "high-dimensional" biological tools and AI-enabled methods to solve the "persistent symptom" puzzle.
Direct Detection: Several finalists are moving toward FDA submission for tests that detect the Borrelia bacteria itself (direct detection) rather than the body's immune response, which can be suppressed or delayed.
1 vue